Related content

New Treatments for Bladder Cancer: When Will We Make Progress?

By Nadal Rosa   Bellmunt Joaquim  

Current Treatment Options in Oncology, Vol. 15, Iss. 1, 2014-03 ,pp. : 99-114

Springer Publishing Company

Access to resources Recommend Favorite

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

By Cirone Pasquale   Andresen Catharine   Eswaraka Jeetendra   Lappin Patrick   Bagi Cedo  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 525-538

Springer Publishing Company

Access to resources Recommend Favorite

Assessment of HER2 status in breast cancer - why, when and how?

By Dowsett M.   Cooke T.   Ellis I.   Gullick W.J.   Gusterson B.   Mallon E.   Walker R.  

European Journal of Cancer, Vol. 36, Iss. 2, 2000-01 ,pp. : 170-176

Elsevier

Access to resources Recommend Favorite

When and How Do I Use Neoadjuvant Chemotherapy for Breast Cancer?

By Rapoport Bernardo   Demetriou Georgia   Moodley Shun   Benn Carol  

Current Treatment Options in Oncology, Vol. 15, Iss. 1, 2014-03 ,pp. : 86-98

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of Functional and Surgical Outcomes of Laparoscopic-Assisted Colonic J-Pouch Versus Straight Reconstruction After Total Mesorectal Excision for Lower Rectal Cancer

By Liang Jin-Tung   Lai Hong-Shiee   Lee Po-Huang   Huang Kuo-Chin  

Annals of Surgical Oncology, Vol. 14, Iss. 7, 2007-07 ,pp. : 1972-1979

Springer Publishing Company

Access to resources Recommend Favorite